Kymera Therapeutics Inc (KYMR)

Feb 27, 2025, 2:48 PM EST - 5 weeks ago

Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 5 weeks ago

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

Jan 30, 2025, 7:00 AM EST - 2 months ago

Kymera Therapeutics to Participate in Upcoming February Investor Conferences

Jan 14, 2025, 7:00 AM EST - 2 months ago

Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Jan 7, 2025, 7:00 AM EST - 3 months ago

Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14

Dec 7, 2024, 1:07 AM EST - 4 months ago

Kymera: Protein Degradation Could Drive Dupixent-Like Value

Nov 26, 2024, 7:00 AM EST - 4 months ago

Kymera Therapeutics to Participate in Upcoming December Investor Conferences

Nov 5, 2024, 7:00 AM EST - 5 months ago

Kymera Therapeutics to Participate in Upcoming November Investor Conferences

Nov 3, 2024, 4:11 PM EST - 5 months ago

Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 7:30 AM EDT - 5 months ago

Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update

Oct 24, 2024, 7:00 AM EDT - 5 months ago

Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

Oct 23, 2024, 7:15 AM EDT - 5 months ago

Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31

Oct 23, 2024, 7:00 AM EDT - 5 months ago

Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium

Oct 9, 2024, 7:00 AM EDT - 6 months ago

Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader

Oct 6, 2024, 2:58 PM EDT - 6 months ago

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Sep 25, 2024, 7:00 AM EDT - 6 months ago

Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress

Aug 28, 2024, 7:00 AM EDT - 7 months ago

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

Aug 21, 2024, 11:15 AM EDT - 8 months ago

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Aug 19, 2024, 10:45 PM EDT - 8 months ago

Kymera Therapeutics Announces Pricing of $225 Million Public Offering

Aug 19, 2024, 4:01 PM EDT - 8 months ago

Kymera Therapeutics Announces Proposed Public Offering

Aug 10, 2024, 11:23 AM EDT - 8 months ago

Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 7:00 AM EDT - 8 months ago

Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7

Jul 16, 2024, 4:58 AM EDT - 9 months ago

Kymera Therapeutics: Solid Progress And No Change To My 'Buy' Rating

Jul 9, 2024, 10:55 AM EDT - 9 months ago

Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Jul 9, 2024, 7:00 AM EDT - 9 months ago

Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day

Jul 8, 2024, 4:05 PM EDT - 9 months ago

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Jun 14, 2024, 7:00 AM EDT - 10 months ago

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Jun 1, 2024, 8:00 AM EDT - 10 months ago

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

May 29, 2024, 7:00 AM EDT - 11 months ago

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

May 23, 2024, 5:00 PM EDT - 11 months ago

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

May 22, 2024, 11:20 AM EDT - 11 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

May 14, 2024, 10:00 AM EDT - 11 months ago

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

May 8, 2024, 7:00 AM EDT - 11 months ago

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

May 3, 2024, 5:07 AM EDT - 1 year ago

Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

Mar 21, 2024, 4:28 PM EDT - 1 year ago

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

SNY

Mar 8, 2024, 10:00 AM EST - 1 year ago

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

Feb 22, 2024, 7:00 AM EST - 1 year ago

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Feb 15, 2024, 7:00 AM EST - 1 year ago

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

Jan 31, 2024, 7:00 AM EST - 1 year ago

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

Jan 9, 2024, 9:17 AM EST - 1 year ago

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

Jan 9, 2024, 9:15 AM EST - 1 year ago

Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 5, 2024, 6:00 AM EST - 1 year ago

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

Jan 4, 2024, 7:00 AM EST - 1 year ago

R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Jan 2, 2024, 7:00 AM EST - 1 year ago

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

Dec 13, 2023, 7:00 AM EST - 1 year ago

Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

Dec 10, 2023, 9:00 PM EST - 1 year ago

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

Dec 7, 2023, 7:00 AM EST - 1 year ago

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi